Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine

J Infect Dis. 1999 Dec;180(6):2018-22. doi: 10.1086/315119.

Abstract

A randomized trial comparing 3 manufacturing consistency lots of a combination hepatitis A/hepatitis B vaccine to each other and to hepatitis A vaccine and hepatitis B vaccine given separately and concurrently was done to evaluate safety, tolerability, and immunogenicity. Healthy volunteers >/=11 years of age were divided into 4 groups. Each of 3 groups received a separate consistency lot of the combination vaccine, and 1 group received separate but concurrent injections of hepatitis A and hepatitis B vaccines. Injections were given at weeks 0 and 24. The combination vaccine was generally well tolerated. The hepatitis A portion of the combination vaccine produced clinically acceptable high seropositivity rates 4 and 52 weeks after the first injection. The hepatitis B portion of the vaccine did not produce clinically acceptable seropositivity rates 4 weeks after the second injection. Lack of antibody production may be attributed, at least in part, to immunologic interference.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Female
  • Hepatitis A Vaccines
  • Hepatitis B Antibodies / biosynthesis*
  • Hepatitis B Surface Antigens / immunology*
  • Hepatitis B Vaccines / administration & dosage
  • Hepatitis B Vaccines / immunology*
  • Hepatitis B virus / immunology
  • Hepatovirus / immunology
  • Humans
  • Male
  • Vaccination
  • Vaccines, Combined / administration & dosage
  • Vaccines, Combined / immunology*
  • Viral Hepatitis Vaccines / administration & dosage
  • Viral Hepatitis Vaccines / immunology*

Substances

  • Hepatitis A Vaccines
  • Hepatitis B Antibodies
  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines
  • Vaccines, Combined
  • Viral Hepatitis Vaccines